April 17th 2025
The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.
February 26th 2025
What Round II of Medicare Part D Drug Prices Signify for the Pharma Industry
January 30th 2025In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, value & access advisor for Schoonveld Advisory and author of The Price of Global Health, comments on the future implications of the latest CMS drug price negotiations.